DiagnosTear plans C$ 1.4 million private placement of units at C$ 0.5 each

• DiagnosTear launched a non-brokered private placement of up to 2,800,000 units at C$ 0.5 each for up to C$ 1.4 million.
• Each unit includes one common share, one warrant exercisable at C$ 1 for 12 months from closing.
• BioLight Life Sciences, its parent, and Elcam Medical may each take up to one-third of the offering.
• Proceeds earmarked for working capital, general corporate purposes.
• Securities will be unregistered in the US; closing requires Canadian Securities Exchange clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Diagnostear Technologies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608310700NEWSFILECNPR____20260831_312119_1) on August 31, 2026, and is solely responsible for the information contained therein.